Biotech faces setbacks after Incyte's experimental cancer drug fails testing - Technical.ly Delaware

Business

Apr. 9, 2018 7:28 am

Biotech faces setbacks after Incyte’s experimental cancer drug fails testing

After a promising start, the Wilmington biotech company announced Friday that its epacadostat trial did not improve patient outcomes.

The results sent ripples across the biotech industry.

(Photo by Flickr user Bill Dickinson, used under a Creative Commons license)

Wilmington-based Incyte’s promising cancer drug, epacadostat, failed in trial that paired it with Merck’s drug Keytruda — a setback for the Wilmington biotech company that caused a dramatic 18 percent drop in its shares Friday.

In a chain reaction, other biotech companies including NewLink Genetics Corp. in Ames, Iowa, and Corvus Pharmaceuticals Inc. in Burlingame, California, also saw their stocks fall.

The Wall Street Journal reported:

Incyte’s drug, epacadostat, was previously viewed as one of the more promising of the next generation of cancer drugs designed to work by harnessing the patients’ own immune systems to destroy tumor cells.

Merck, Bristol-Myers Squibb Co. and other companies sell older types of immunotherapies that have improved treatment for certain cancers including the skin cancer melanoma and lung cancer. The market for these drugs is booming: Merck’s global Keytruda sales more than doubled to $3.8 billion last year.

But they don’t work for every patient, so companies have been racing to test whether combining older immunotherapies with other drugs could further improve patient survival.

Although promising in early trials, it was found in a larger trial launched in 2016 that the combination of epacadostat and Keytruda did not improve outcomes in test patients.

Last summer, an AstraZeneca study testing two PLC immunotherapies for lung cancer failed, calling into question the effectiveness of previously promising combination drug therapy.

Read the full story -30-
LEAVE A COMMENT

Advertisement

Hatch House Wilmington is done, and Steve Boerner is trying something new

The best way to cancel a workshop no one signed up for

Cool job alert: Use tech to help make food safer

SPONSORED

Delaware

10 Delaware brands totally crushing it on social media

NY, PA, DC, Virtual

SAP

Senior Account Executive, SAP SuccessFactors

Apply Now
Towson, Maryland

Stanley Black and Decker (GTS)

Software Engineer – Breakthrough Innovation

Apply Now

Why this UD entrepreneur’s Christmas sweater ecommerce shop failed

After shutting down his startup, UD grad Ben Rapkin reflects on what he’s learned

Federal jury asks Gilead to pay Merck $2.54 billion in royalties in patent infringement case

SPONSORED

Delaware

13 innovative technologies being developed in Delaware

Towson, Maryland or Atlanta, GA

Stanley Black and Decker (GTS)

IoT Digital Architect – Breakthrough Innovation

Apply Now
Market St., Wilmington, DE

DelawareIQ

Marketing Intern

Apply Now
Gurgaon

Mobi India

iOS Application Development

Apply Now

Sign-up for regular updates from Technical.ly

Do NOT follow this link or you will be banned from the site!